Navigation Links
CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
Date:2/23/2010

CAMBRIDGE, England, February 23, 2010 /PRNewswire/ -- From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

Under the terms of the new agreement, CellCentric will receive from Takeda Pharmaceutical Company Limited an upfront payment and pre-clinical and clinical milestones, in addition to royalties. Based on the royalties and milestones defined, the overall deal could be worth in excess of $200m to CellCentric over the course of the agreement.

This is a pioneering deal for the emerging area of epigenetics, demonstrating the commercial interest in novel epigenetic targets beyond HDACs (histone deacetylases) and DNMTs (DNA methyltransferases ). Therapeutic research will be initiated by Takeda's Research Group. Development of molecules stemming from this agreement will be completed by Millennium: The Takeda Oncology Company, which is responsible for Takeda's global oncology development strategy.

Many diseases including cancer involve a loss of cell fate control. In many cases this is associated with aberrant epigenetic changes to chromatin: dynamic modifications of DNA and its associated proteins, including histones. These epigenetic alterations are caused by a range of enzymes. Initial therapeutic interest has been focused on inhibiting HDAC and DNMTs. It has become increasingly clear that there are many other key epigenetic related enzymes that can be targeted and which may offer greater specificity of action. These include histone methyltransferases, demethylases and ubiquitin-related enzymes.

CellCentric has an innovation platform built upon relationships with over 30 world leading research labs in epigenetics. The company has identified and prioritised multiple next generation targets and runs a series of active drug discovery programmes from its centre in Cambridge, UK. As programmes move forward, CellCentric is able to gain continued benefit and support from multiple Principal Investigators within its network.

With an extensive portfolio and rich pipeline, CellCentric's strategy is to develop some target programmes through licences and collaborations with Pharmaceutical companies while retaining other programmes for development itself.

Dr Hiroyuki Odaka, General Manager of the Pharmaceutical Research Division of Takeda said "Epigenetics is an important area for novel oncology therapeutics. This new agreement demonstrates our commitment to researching and pioneering the best ways to treat cancer."

Dr Will West, CEO of CellCentric added "This licence is a strong endorsement of the way we are approaching innovation in epigenetics. This is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armoury for tackling intractable diseases such as cancer".

Notes:

CellCentric is a biotechnology company focused on epigenetics. Formed in 2004, it works with over 30 academic labs worldwide to identify, patent and commercialise product opportunities. CellCentric currently has 7 novel target discovery programmes ongoing, focused on cancer, as well as multiple projects related to reprogramming and epigenetic tools. For further details on the company, see: http://www.cellcentric.com.

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website http://www.takeda.com.

SOURCE CellCentric Ltd

Back to top
'/>"/>
SOURCE CellCentric Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
2. TenX Biopharma Licenses Zanolimumab From Genmab
3. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
4. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke
7. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
8. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
9. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
10. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
11. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... 12, 2016 Indiso ... den ungedeckten medizinischen Bedarf bei Lungen- und ... klinischen Forschungsprogramms bekannt. Das Programm, das sich ... ihrer respiratorischen Funktionen und anderer klinischer Parameter. ... Medizintechnikunternehmen, das sich auf den ungedeckten medizinischen ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips on ... of Rama - Dr. Frederick Lenz. , According to Publisher Roger Cantu, ... teacher for teaching and helping others. Valentine’s Day celebrates love in all its ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... CITY, California (PRWEB) , ... February 12, 2016 , ... ... announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre ... healthy way to stay hydrated before the big event. The invitation-only gifting suite, held ...
(Date:2/12/2016)... ... 2016 , ... Every winter, someone is killed, injured or loses a home ... Center, part of the Allegheny Health Network, has partnered with Etna Volunteer Fire ... Need Space” campaign. , “Space Heaters Need Space” aims to bring awareness ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert ... to Know in 2016 . The list consists of physicians establishing, leading and partnering ... this list. , An Ambulatory Surgery Center, also known as an ASC, is ...
Breaking Medicine News(10 mins):